Markus Magerl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2021050/publications.pdf

Version: 2024-02-01

140 papers	8,696 citations	47006 47 h-index	49909 87 g-index
163 all docs	163 docs citations	163 times ranked	4385 citing authors

#	Article	IF	Citations
1	The EAACI/GAÂ²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	5.7	1,008
2	The international EAACI/GAÂ²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
3	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€"The 2017 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1575-1596.	5.7	365
4	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 780-802.	5.7	268
5	WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organization Journal, 2012, 5, 182-199.	3.5	264
6	Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. British Journal of Dermatology, 2006, 154, 294-298.	1.5	189
7	Omalizumab treatment in patients with chronic inducible urticaria: AÂsystematic review of published evidence. Journal of Allergy and Clinical Immunology, 2018, 141, 638-649.	2.9	187
8	Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.	5.7	182
9	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. JAMA - Journal of the American Medical Association, 2018, 320, 2108.	7.4	174
10	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€"The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	5.7	153
11	Successful treatment of solar urticaria with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1563-1565.	5.7	149
12	Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.	5.7	147
13	New topics in bradykinin research. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1397-1406.	5.7	146
14	The German version of the chronic urticaria qualityâ€ofâ€life questionnaire: factor analysis, validation, and initial clinical findings. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 927-936.	5.7	145
15	The definition and diagnostic testing of physical and cholinergic urticarias â€“ EAACI/GA²LEN/EDF/UNEV consensus panel recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1715-1721.	5.7	143
16	Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy and Asthma Proceedings, 2012, 33, 145-156.	2.2	142
17	Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme: Implications for Hair Growth Control. Journal of Investigative Dermatology, 2003, 120, 895-904.	0.7	135
18	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133

#	Article	IF	Citations
19	Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. Dermatology, 2006, 212, 150-159.	2.1	120
20	Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet Journal of Rare Diseases, 2018, 13, 73.	2.7	114
21	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	1.3	110
22	Definition, aims, and implementation of <scp>GA</scp>²<scp>LEN</scp> Urticaria Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1210-1218.	5.7	110
23	Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy, Asthma and Clinical Immunology, 2013, 9, 29.	2.0	107
24	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
25	Effects of a pseudoallergenâ€free diet on chronic spontaneous urticaria: a prospective trial. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 78-83.	5.7	102
26	The Angioedema Quality of Life Questionnaire (<scp>AE</scp>â€QoL) â€“ assessment of sensitivity to change and minimal clinically important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1203-1209.	5.7	92
27	Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. New England Journal of Medicine, 2018, 379, 352-362.	27.0	89
28	Simple and rapid method to isolate and culture follicular papillae from human scalp hair follicles. Experimental Dermatology, 2002, 11, 381-385.	2.9	84
29	Patterns of Proliferation and Apoptosis during Murine Hair Follicle Morphogenesis. Journal of Investigative Dermatology, 2001, 116, 947-955.	0.7	83
30	Successful treatment of delayed pressure urticaria with antiâ€“TNF-Î±. Journal of Allergy and Clinical Immunology, 2007, 119, 752-754.	2.9	81
31	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80
32	Hereditary angioedema (HAE) in children and adolescentsâ€”a consensus on therapeutic strategies. European Journal of Pediatrics, 2012, 171, 1339-1348.	2.7	80
33	Mast cellâ€“driven skin inflammation is impaired in the absence of sensory nerves. Journal of Allergy and Clinical Immunology, 2008, 121, 955-961.	2.9	75
34	Executive summary of the methods report for â€˜The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Updateâ€™. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1145-1146.	5.7	74
35	Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Journal of Allergy and Clinical Immunology, 2009, 123, 705-706.	2.9	67
36	Peltier effectâ€“based temperature challenge: An improved method for diagnosing cold urticaria. Journal of Allergy and Clinical Immunology, 2004, 114, 1224-1225.	2.9	63

#	Article	IF	Citations
37	Hereditary angioedema: Molecular and clinical differences among European populations. Journal of Allergy and Clinical Immunology, 2015, 135, 570-573.e10.	2.9	63
38	Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 303-305.	5.7	61
39	Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. British Journal of Dermatology, 2010, 162, 674-676.	1.5	59
40	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	2.9	59
41	Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1â€inhibitor concentrate. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1319-1328.	5.7	59
42	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1793-1802.e2.	3.8	58
43	Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H ₁ â€antihistamine dose escalation. British Journal of Dermatology, 2012, 166, 1095-1099.	1.5	53
44	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
45	Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme During the Hair Growth Cycle: Implications for Growth Control and Hair Follicle Transformations. Journal of Investigative Dermatology Symposium Proceedings, 2003, 8, 80-86.	0.8	51
46	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 477-478.	0.8	51
47	Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 963-971.	3.8	50
48	Validation of the Angioedema Control Test (AECT)â€"A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	3.8	50
49	Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. British Journal of Dermatology, 2010, 162, 198-200.	1.5	49
50	Nonâ€pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells. Experimental Dermatology, 2008, 17, 427-435.	2.9	47
51	Development of the Angioedema Control Testâ€"A patientâ€reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
52	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
53	Rupatadine improves quality of life in mastocytosis: a randomized, doubleâ€blind, placeboâ€controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
54	The international WAO/EAACI guideline for the management of hereditary angioedema â€“ the 2017 revision and update. World Allergy Organization Journal, 2018, 11, 5.	3.5	45

#	Article	IF	Citations
55	Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clinical and Experimental Dermatology, 2014, 39, 298-303.	1.3	44
56	Hereditary Angioedema with Normal C1 Inhibitor. Immunology and Allergy Clinics of North America, 2017, 37, 571-584.	1.9	43
57	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 901-911.	3.8	43
58	F12â€46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1661-1664.	5.7	42
59	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-978.	0.8	39
60	Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cellâ€"Mediated Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 61, 40-49.	6.5	39
61	Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1465-1468.	5.7	38
62	The international WAO/EAACI guideline for the management of hereditary angioedema â€" The 2021 revision and update. World Allergy Organization Journal, 2022, 15, 100627.	3.5	37
63	A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clinical and Experimental Dermatology, 2013, 38, 360-366.	1.3	35
64	An improved Peltier effectâ€based instrument for critical temperature threshold measurement in coldâ€• and heatâ€induced urticaria. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2043-2045.	2.4	35
65	Longâ€term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 979-990.	5.7	33
66	Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Gene, 2018, 667, 76-82.	2.2	32
67	Guideline: Hereditary angioedema due to C1 inhibitor deficiency. Allergo Journal International, 2019, 28, 16-29.	2.0	32
68	Limitations of human occipital scalp hair follicle organ culture for studying the effects of minoxidil as a hair growth enhancer. Experimental Dermatology, 2004, 13, 635-642.	2.9	31
69	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>â€2Âstudy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1871-1880.	5.7	31
70	Histamine intolerance in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1774-1777.	2.4	29
71	Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. Clinical and Translational Allergy, 2018, 8, 42.	3.2	29
72	Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	5.7	29

#	Article	IF	Citations
73	Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). Journal of Dermatological Science, 2011, 62, 36-41.	1.9	28
74	Longâ€term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-107.	0.8	28
75	Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset. International Archives of Allergy and Immunology, 2017, 174, 200-204.	2.1	28
76	Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings, 2017, 38, 143-151.	2.2	28
77	An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clinical and Translational Allergy, 2017, 7, 36.	3.2	28
78	Impact of lanadelumab on healthâ€related quality of life in patients with hereditary angioedema in the HELP study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1188-1198.	5.7	28
79	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. Journal of the American Academy of Dermatology, 2021, 84, 691-700.	1.2	28
80	Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2022, 399, 945-955.	13.7	28
81	Consensus on treatment goals in hereditary angioedema: AÂglobal Delphi initiative. Journal of Allergy and Clinical Immunology, 2021, 148, 1526-1532.	2.9	27
82	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	5.7	26
83	Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds. Mycoses, 2009, 52, 334-338.	4.0	25
84	Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clinical and Experimental Dermatology, 2015, 40, 399-403.	1.3	25
85	Prophylaxis of hereditary angioedema attacks: AÂrandomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology, 2016, 138, 934-936.e5.	2.9	25
86	Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2017, 118, 110-112.	1.0	24
87	Randomized, doubleâ€blind, placeboâ€controlled study of safety and efficacy of miltefosine in antihistamineâ€resistant chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e363-9.	2.4	23
88	Mast cells determine the magnitude of bacterial toxinâ€induced skin inflammation. Experimental Dermatology, 2009, 18, 160-166.	2.9	22
89	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.4	22
90	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2073-2075.	5.7	22

#	Article	IF	Citations
91	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20â€ƒmg. Clinical and Experimental Dermatology, 2009, 34, e137-e140.	1.3	21
92	Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 119-120.	2.4	21
93	Practical Approach to Self-Administration of Intravenous C1-INH Concentrate: A Nursing Perspective. International Archives of Allergy and Immunology, 2013, 161, 17-20.	2.1	21
94	Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema. Allergy and Rhinology, 2017, 8, ar.2017.8.0192.	1.6	21
95	The Diagnostic Workup in Chronic Spontaneous Urticariaâ€”What to Test and Why. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2274-2283.	3.8	21
96	Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1747-1754.	2.4	20
97	A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. Allergology International, 2020, 69, 443-449.	3.3	19
98	Treatment of notalgia paraesthetica with an 8% capsaicin patch. British Journal of Dermatology, 2011, 165, 1359-1361.	1.5	18
99	Langzeitprophylaxe des hereditÃren AngioÃ¶dems mit Androgenderivaten: kritische Bewertung und mÃ¶gliche Alternativen. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-108.	0.8	18
100	Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatric Allergy and Immunology, 2019, 30, 562-568.	2.6	18
101	Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. Annals of Allergy, Asthma and Immunology, 2009, 102, 495-499.	1.0	17
102	Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey. Allergy and Rhinology, 2016, 7, ar.2016.7.0165.	1.6	17
103	Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1142-1145.	3.8	17
104	Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3744-3751.	3.8	17
105	Hereditary angioedema: an update on available therapeutic options. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-672.	0.8	16
106	Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. JDDG - Journal of the German Society of Dermatology, 2016, 14, 266-275.	0.8	16
107	Hereditary angioedema in children and adolescents â€“ A consensus update on therapeutic strategies for Germanâ€speaking countries. Pediatric Allergy and Immunology, 2020, 31, 974-989.	2.6	16
108	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 61, 84-97.	6.5	16

#	Article	IF	Citations
109	Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 224-226.	5.7	15
110	HereditÃres AngioÃ¶dem: Update zu verfÃ¼gbaren Therapieoptionen. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-673.	0.8	14
111	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organization Journal, 2020, 13, 100475.	3.5	13
112	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. World Allergy Organization Journal, 2021, 14, 100542.	3.5	11
113	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
114	An analysis of the teaching of intravenous self-administration in patients with hereditary angio-oedema. Clinical and Experimental Dermatology, 2016, 41, 366-371.	1.3	10
115	Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings, 2016, 37, 489-500.	2.2	10
116	Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases, 2021, 16, 86.	2.7	10
117	Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema. Clinical and Experimental Dermatology, 2016, 41, 91-93.	1.3	9
118	Clinical Utility Gene Card for hereditary angioedema with normal C1 inhibitor (HAEnC1). European Journal of Human Genetics, 2017, 25, e1-e4.	2.8	9
119	How to control recurrent angioedema using monoclonal antibody therapies?. Expert Opinion on Biological Therapy, 2020, 20, 1-4.	3.1	9
120	A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet Journal of Rare Diseases, 2020, 15, 221.	2.7	9
121	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy, 2021, 11, e12089.	3.2	9
122	Prophylaxe beim hereditÃren AngioÃ¶dem (HAE) mit C1â€Inhibitormangel. JDDG - Journal of the German Society of Dermatology, 2016, 14, 266-276.	0.8	8
123	Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 163-169.	2.4	8
124	Automatic screening of selfâ€evaluation apps for urticaria and angioedema shows a high unmet need. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3810-3813.	5.7	8
125	Erfolgreiche Behandlung des hereditÃren AngioÃ¶dems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	7
126	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. JDDG - Journal of the German Society of Dermatology, 2020, 18, 737-739.	0.8	6

#	Article	IF	Citations
127	Successful treatment of hereditary angioedema with bradykinin B2â€receptor antagonist icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	5
128	Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology, 2015, 135, AB192.	2.9	5
129	Daily subcutaneous administration of human C1 inhibitor in a child with hereditary angioedema type 1. Pediatric Allergy and Immunology, 2016, 27, 223-224.	2.6	5
130	C1 Inhibitor for Routine Prophylaxis in Patients with Hereditary Angioedema: Interim Results from a European Registry Study. Journal of Allergy and Clinical Immunology, 2016, 137, AB251.	2.9	5
131	Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. Allergy, Asthma and Clinical Immunology, 2022, 18, 4.	2.0	5
132	BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study. Journal of Allergy and Clinical Immunology, 2015, 135, AB278.	2.9	4
133	Subcutaneous Human C1-Inhibitor with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema: Results of a Randomized, Double-Blind, Dose-Ranging, Crossover Study. Journal of Allergy and Clinical Immunology, 2015, 135, AB278.	2.9	4
134	HAE patient self-sampling for biomarker establishment. Orphanet Journal of Rare Diseases, 2021, 16, 399.	2.7	4
135	Prevalence and relevance of skin autoreactivity in chronic urticaria. Expert Review of Dermatology, 2009, 4, 655-663.	0.3	3
136	Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE). Frontiers in Allergy, 0, 3, .	2.8	2
137	Pharmacokinetics of Subcutaneous C1 Esterase Inhibitor (human) with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema. Journal of Allergy and Clinical Immunology, 2015, 135, AB192.	2.9	1
138	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 476-477.	0.8	1
139	Analysis of genetic impact on smell impairment in patients with hereditary angioedema typeÂ1 and 2. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1060-1062.	0.8	0
140	Inducible Urticarias. , 2021, , 109-132.		0